Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Coley initiates Phase I study for SLE drug
The candidate, CPG 52364, is a small molecule toll-like receptor (TLR) antagonist designed to specifically inhibit TLRs 7, 8 and 9 and inhibit disease development in systemic lupus
The candidate, CPG 52364, is a small molecule toll-like receptor (TLR) antagonist designed to specifically inhibit TLRs 7, 8 and 9 and inhibit disease development in systemic lupus
Under the terms of the agreement, River’s Edge acknowledges the validity and enforceability of the Nicomide patent. River’s Edge has agreed to make a lump-sum settlement payment to
The approvable letter relates to the use of Mucinex with Codeine in the prescription treatment of cough associated with the common cold, inhaled irritants and stable chronic bronchitis.
The preliminary results of the Phase I/II trial demonstrated that CTCE-9908 is well tolerated with no dose limiting toxicity observed up to the maximum dose of 5mg/kg/day that
The company expects that the Phase II clinical trial will provide a robust statistical assessment, confirm the proposed dosing regimen and support the initiation of a Phase III
Under the termination agreement, Novavax will complete the manufacture of remaining orders for the product and plans to close its Philadelphia manufacturing facility over the next few months.
The study is an open-label, multi-center, six-week trial conducted in hospitalized patients with treatment resistant schizophrenia, in which BL-1020 showed statistically significant efficacy with minimal side effects. The
ViraNative filed for bankruptcy in September and Swedish Orphan International acquired the bankruptcy estate. Through this takeover Swedish Orphan International has acquired the worldwide rights for the drug
The multi-center blood conservation using antifibrinolytics (BART) trial was comparing the efficacy and safety of the use of aprotinin (Trasylol), aminocaproic acid and tranexamic acid in approximately 3000
The drug candidate ELND-005/AZD-103 has undergone Phase I clinical trials and appears to be safe and well tolerated at all doses and dosing regimes examined in approximately 110